138 related articles for article (PubMed ID: 23959725)
21. Hepatic peroxisomal fatty acid beta-oxidation is regulated by liver X receptor alpha.
Hu T; Foxworthy P; Siesky A; Ficorilli JV; Gao H; Li S; Christe M; Ryan T; Cao G; Eacho P; Michael MD; Michael LF
Endocrinology; 2005 Dec; 146(12):5380-7. PubMed ID: 16123164
[TBL] [Abstract][Full Text] [Related]
22. Endurance training-induced accumulation of muscle triglycerides is coupled to upregulation of stearoyl-CoA desaturase 1.
Dobrzyn P; Pyrkowska A; Jazurek M; Szymanski K; Langfort J; Dobrzyn A
J Appl Physiol (1985); 2010 Dec; 109(6):1653-61. PubMed ID: 20847127
[TBL] [Abstract][Full Text] [Related]
23. Palmitic acid-induced apoptosis in pancreatic β-cells is increased by liver X receptor agonist and attenuated by eicosapentaenoate.
Liang H; Zhong Y; Zhou S; Li QQ
In Vivo; 2011; 25(5):711-8. PubMed ID: 21753123
[TBL] [Abstract][Full Text] [Related]
24. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T; Ide T; Shimano H; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Yatoh S; Kitamine T; Okazaki H; Tamura Y; Sekiya M; Takahashi A; Hasty AH; Sato R; Sone H; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1240-54. PubMed ID: 12730331
[TBL] [Abstract][Full Text] [Related]
25. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Coll T; Alvarez-Guardia D; Barroso E; Gómez-Foix AM; Palomer X; Laguna JC; Vázquez-Carrera M
Endocrinology; 2010 Apr; 151(4):1560-9. PubMed ID: 20185762
[TBL] [Abstract][Full Text] [Related]
26. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
[TBL] [Abstract][Full Text] [Related]
27. Effect of liver X receptor activation on the very low density lipoprotein secretion and messenger ribonucleic acid level of related genes in goose primary hepatocytes.
Han CC; Wang JW; Pan ZX; Tang H; Xiang SX; Wang J; Li L; Xu F; Wei SH
Poult Sci; 2011 Feb; 90(2):402-9. PubMed ID: 21248338
[TBL] [Abstract][Full Text] [Related]
28. Metabolic switching of human myotubes is improved by n-3 fatty acids.
Hessvik NP; Bakke SS; Fredriksson K; Boekschoten MV; Fjørkenstad A; Koster G; Hesselink MK; Kersten S; Kase ET; Rustan AC; Thoresen GH
J Lipid Res; 2010 Aug; 51(8):2090-104. PubMed ID: 20363834
[TBL] [Abstract][Full Text] [Related]
29. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor.
Inaba T; Matsuda M; Shimamura M; Takei N; Terasaka N; Ando Y; Yasumo H; Koishi R; Makishima M; Shimomura I
J Biol Chem; 2003 Jun; 278(24):21344-51. PubMed ID: 12672813
[TBL] [Abstract][Full Text] [Related]
30. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
[TBL] [Abstract][Full Text] [Related]
31. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146
[TBL] [Abstract][Full Text] [Related]
32. Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells.
Bai Q; Xu L; Kakiyama G; Runge-Morris MA; Hylemon PB; Yin L; Pandak WM; Ren S
Atherosclerosis; 2011 Feb; 214(2):350-6. PubMed ID: 21146170
[TBL] [Abstract][Full Text] [Related]
33. [Effect of liver X receptors agonists T0901317 on expression of FAT/CD36 gene mRNA in adult human skeletal muscle cell].
Zeng R; Sa YL; Yan XM
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2009 Aug; 25(3):428-32. PubMed ID: 21155254
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
35. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
Zheng F; Zhang S; Lu W; Wu F; Yin X; Yu D; Pan Q; Li H
PLoS One; 2014; 9(6):e101269. PubMed ID: 24972069
[TBL] [Abstract][Full Text] [Related]
36. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of lipogenesis as well as fatty acid oxidation protects against palmitate-induced INS-1 beta-cell death.
Choi SE; Jung IR; Lee YJ; Lee SJ; Lee JH; Kim Y; Jun HS; Lee KW; Park CB; Kang Y
Endocrinology; 2011 Mar; 152(3):816-27. PubMed ID: 21209018
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.
Grefhorst A; Elzinga BM; Voshol PJ; Plösch T; Kok T; Bloks VW; van der Sluijs FH; Havekes LM; Romijn JA; Verkade HJ; Kuipers F
J Biol Chem; 2002 Sep; 277(37):34182-90. PubMed ID: 12097330
[TBL] [Abstract][Full Text] [Related]
40. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
